1 international co-operation in radiation oncology: philip poortmans, md, phd on behalf of the eortc...
Post on 25-Dec-2015
219 Views
Preview:
TRANSCRIPT
1
International co-operation in radiation
oncology:
Philip Poortmans, MD, PhDOn behalf of the EORTC Radiation Oncology Group
Prepared for a meeting in January 2010
2
• 300 hospitals/cancer centres in > 30 countries;
• ~ 2,900 collaborators involved in cancer treatment and research;
• ~ 5,000 new patients enrolled each year;
• ~ 50 trials open to patient entry;
• ~ 50,000 patients in follow-up;
• database of > 150,000 patients.
3
4
5
6
• 1962, Henri Tagnon and a few pioneers: GECA
• 1968 renamed into EORTC
• 1962: Maurice Tubiana, Klaas Breur and Jacques Henry: Radio-Chemotherapy Group: first Hodgkin trials
• 1973: split Hodgkin & Non-HodgkinGroup (later Lymphoma Group) and Radiotherapy Group
• January 10, 1975 in Creteil: first independent meeting with Claude Lalanne, Jean-Claude Goffin, Alain Laugier and Jean-Claude Horiot
• 1978, first protocol: V-22781, pelvic radiotherapy versus extended fields to para-aortic nodes in cervix cancers
• Emmanuel van der Schueren, Jean-Claude Horiot and Walter van den Bogaert: altered fractionation schemes and radio-sensitisers
• Karl-Axel Johansson, Emmanuel van der Schueren, Jean-Claude Horiot, Guido Garavaglia, Harry Bartelink, Jacques Bernier, Bernard Davis and many others: QA
• Joint research ventures with other EORTC groups; Urology, Gastro-Intestinal, Brain and Breast
• Nineties: "mega-trials“
• Restructuring meetings in parallel sessions for disease-oriented working parties
• 21st century: more than 3500 patients: >> other EORTC groups
• Evaluation of high precision radiotherapy: 3D-CRT & IMRT
• 2006: renamed into “Radiation Oncology Group”
7
Aims:• To improve local control and survival• To improve organ preservation • To improve quality of life • To improve treatment management and QA in RT
departmentsStrategies:• Elaboration of new randomised trials aiming at the most efficient integration of radiotherapy
with other treatment modalities (i.e. surgery, chemotherapy, hormone therapy) into a whole range of cancer sites, in close cooperation with other EORTC groups or international organisations
• Integration of innovative modalities into radiotherapy such as new classes of therapeutic agents (radiation modifiers, anti-angiogenesis compounds and gene therapy)
• Integration of novel radiation techniques such as IMRT, allowing dose-escalation studies
8
Aims:• To improve local control and survival• To improve organ preservation • To improve quality of life • To improve treatment management and QA in RT departments
Strategies:• Elaboration of new randomised trials aiming at the most
efficient integration of radiotherapy with other treatment modalities (i.e. surgery, chemotherapy, hormone therapy) into a whole range of cancer sites, in close cooperation with other EORTC groups or international organisations
• Integration of innovative modalities into radiotherapy such as new classes of therapeutic agents (radiation modifiers, anti-angiogenesis compounds and gene therapy)
• Integration of novel radiation techniques such as IMRT, allowing dose-escalation studies
9
Aims:• To improve local control and survival• To improve organ preservation • To improve quality of life • To improve treatment management and QA in RT departments
Strategies:• Elaboration of new randomised trials aiming at the most efficient integration of radiotherapy with other
treatment modalities (i.e. surgery, chemotherapy, hormone therapy) into a whole range of cancer sites, in close cooperation with other EORTC groups or international organisations
• Integration of innovative modalities into radiotherapy such as new classes of therapeutic agents (radiation modifiers, anti-angiogenesis compounds and gene therapy)
• Integration of novel radiation techniques such as IMRT, allowing dose-escalation studies
10
Aims:• To improve local control and survival• To improve organ preservation • To improve quality of life • To improve treatment management and QA in RT departments
Strategies:• Elaboration of new randomised trials aiming at the most efficient integration of radiotherapy with other
treatment modalities (i.e. surgery, chemotherapy, hormone therapy) into a whole range of cancer sites, in close cooperation with other EORTC groups or international organisations
• Integration of innovative modalities into radiotherapy such as new classes of therapeutic agents (radiation
modifiers, anti-angiogenesis compounds and gene therapy)
• Integration of novel radiation techniques such as IMRT, allowing dose-escalation studies
11
• Early external irradiation improves progression-free survival in low grade astrocytoma and oligodendroglioma. Karim et al. IJROBP 2002.
• Low dose irradiation to the para-aortic nodes and liver does not improve survival for resected adenocarcinoma of the rectum. Bosset et al. R&O 2001.
• Results boost/no boost study: a boost of 16 Gy to the tumour bed reduces the risk of local recurrence. Bartelink et al. NEJM 2001 & JCO 2007.
• Dummy run procedure identifies potential systematic protocol deviations, avoidable by provision of recommendations. Poortmans et al. IJROBP 2001.
• Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer. Bolla et al. Lancet 2002.
• Post-operative irradiation with concomitant cisplatinum improves DFS and OS of high-risk locally advanced H&N cancer patients. Bernier et al. NEJM 2004.
12
• Post-operative radiotherapy after radical prostatectomy improves DFS of patients with cT2/pT3 prostate cancer. Bolla et al: Lancet 2005.
• Concomitant chemotherapy enhances the tumorocidal effect of pre-operative irradiation in patients with rectal cancer. Bosset et al. JCO 2005.
• Concomitant chemotherapy by temozolomide improves OS of patients with glioblastoma multiforme treated by radiotherapy. Stupp et al. NEJM 2005.
• Breast-conserving treatment with or without radiotherapy for DCIS: Ten-year results. Bijker et al: JCO 2006.
• Chemotherapy with preoperative radiotherapy in rectal cancer. Bosset et al: N Engl J Med 2006.
• Quality assurance works. Poortmans et al: Strahlenther Onkol 2006.
• Guidelines for primary/post-operative radiotherapy of patients with prostate cancer. Boehmer/Poortmans et al: Radiother Oncol 2006 & 2007.
13
• Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Girinsky et al: Radiother Oncol 2006 & 2008.
• Prophylactic Cranial Irradiation in Extensive Disease Small Cell Lung Cancer. Slotman et al: N Engl J Med 2007.
• Standard versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer. Le Péchoux et al: Lancet Oncol 2009.
• Long term or short term androgen suppression combined with irradiation in locally advanced prostate cancer. Bolla et al: N Engl J Med 2009.
• Radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Matzinger et al: Radiother Oncol 2009.
• Impact of the boost dose in patients with early stage breast cancer after a microscopically incomplete lumpectomy. Poortmans et al: Radioth Oncol 2009.
14
CONCLUSION
These advances have been progressively translated into daily clinical
practice, demonstrating the EORTC Radiation Oncology Group’s
contribution to improving results using new radiotherapy
techniques alone or in combination with other modalities
15
ROG Executive Committee
Steering Committee:ROG Executive
QA RT Strategic Ctee & QA RT Team Chairs
ROG Working Party Coordinators
ROG Study Coordinators
ROG Committee Chairs:
Website and PR Committee: A. Kuten
Membership Committee: A. van den Bergh
Publication Committee: D. Weber
Chair RTT Group: F. Duclos
Young Oncologist: E. Dieleman, Amsterdam
EORTC Headquarters Team
Co-chairs of joint studies
Vincent Grégoire
(Brussels)Chair
Karin Haustermans
(Leuven)Post-chair
Edwin Aird Physics Co-
chair QA RT Team
Coen Hurkmans Physics Co-
chair QA RT SC
Philippe Maingon(Dijon)
Treasurer
Damien Weber Clinical Co-chair QA RT SC/Team
16
Breast Cancer: Helen Westenberg (Arnhem, NL)
Abraham Kuten (Haifa, IL)
Lung Cancer: Cécile Le Péchoux (Villejuif, F)
Head and Neck Cancer: Wilfried Budach (Düsseldorf, D)
Hans Langendijk (Groningen, NL)
Gastro-intestinal Tract: Oscar Matzinger (Lausanne, CH),
Philippe Maingon (Dijon, F)
Genito-urinary Cancer: Christopher Scrase (Ipswich, UK)
Fons van den Bergh (Groningen,
NL)
Brain Tumours: Damien Weber (Geneva, CH)
Sara Erridge (Edinburgh, UK)
17
Frederic Duclos(Lausanne)
Chair & Contact person
Marjolein van Os(Rotterdam)
Scientific supervisor
Hans Paul van der Laan
(Groningen)Scientific supervisor
Bruno Speleers (Gent)
Projects supervisor
Bert Pastoors(Geneve) Secretary
P. Maingon(Dijon)
Treasurer
English, Catalan, French, Italian, Spanish
18
Current ROG trialsCurrent ROG trials
Trial number Status
22071-24071Head – NeckStudy Coordinator: W Budach
Full protocol in development Educational grant Accrual: Pre-study: / 150 pts Main study: / 800 pts
22042-26042MeningiomaStudy Coordinator: Damien Weber
Open23 pts/68 (07.12.09)Academic trial
22043-30041ProstateStudy Coordinator: M Bolla - H Van Poppel
OpenAccrual: 2 / 600 pts (07.12.2009)Educational grant
22085-10083 DCISMailbox (TROG/BIG study)Study Coordinator: H. Westenberg
Regulatory in processAcademic trialAccrual: 200 pts (EORTC+BOOG) / 610 (total)
22051-10052 SupremoMailbox (ISD lead)Study Coordinator: G. Van Tienhoven
Open128 EORTC (07.12.09) / 579 in total (23.11.09)Academic trial
22991 ProstateStudy Coordinator: M. Bolla
Closed (30/04/2008) Accrual: 819 / 800 pts Academic trial
22073-26072GlioblastomaStudy Coordinator: A Grosu
On holdAcademic trial
19
Trial number Specific items / Problems / Action
20971-22997 Lymphoma Closed 2009
10981-22023 AMAROS Accruing; end expected 2010
26082-22081: Temsirolimus Under preparation
26053-22054 CATNON, Anaplastic Glioma Open
26062-22061 Elderly GBM Mailbox (Canada lead) Open
22033-26033 Low grade Gliomas Accruing
26081-22086 Codeleted Mailbox (NCCTG lead) Under preparation
26071-22072 Cilengitide Starting; QA lead by EORTC ROG
2609X-2209X Under preparation
08072-22074 CONVERT 1 site to be opened in the NL, Slovenia and Poland still not opened
40013-22012 Pancreas Closed. Full paper is being drafted.
40054- 22062 PETACC6 Intergroup, EORTC lead Accruing
40084-22084 (RTOG0848) Under preparation. ERDA site study is being developed.
40081-22083 IMAGE trial Under preparation
Closed. Imaging review started.
Closed
24081-22082: locally advanced HN Under preparation
Trials, not ROG-leadTrials, not ROG-lead
20
ChallengesChallenges
• Complexity of the organisation of clinical trials.
• Costs related to the conduct of clinical trials.
• Limited nr of members accrue majority of patients.
time and money
dependency of supporters (companies!)
21
22
23
24
25
EORTC HQ and ROG / QART
Full-time employed at HQFull-time employed at HQ EvdS fellow (radiation oncologist)EvdS fellow (radiation oncologist) QART manager (medical physicist)QART manager (medical physicist)
Main responsibilitiesMain responsibilities CoordinationCoordination PreparationPreparation OrganizationOrganization ReportReport
Professional volunteersProfessional volunteers 3 radiation oncologist3 radiation oncologist 4 medical physicist4 medical physicist 1 radiation technologist1 radiation technologist
Main responsibilitiesMain responsibilities Expert opinionExpert opinion Determination of QART levelDetermination of QART level Validation / finalizationValidation / finalization
EORTCHeadquarters
EORTC Radiation Oncology Group
QART committeeHQ QART
EORTC trial with radiotherapy
QART team =ROG + HQ QART
26
The need for global cooperation and harmonisation
27ICARO 28 April 2009, Vienna
Project proposal: GloVal
GLObal VALidation of clinical trials radiation therapy quality assurance software using a
sustainable DICOM dataset
28
Forum on program harmonisation
Forum on digital data handling
Global trial RTQA harmonisation
ICARO 28 April 2009, Vienna
29
Project goals
Commonly accessible DICOM dataset for validation
testing of RTQA software tools.
Clinical validation test protocol for RTQA software
based on international guidelines.
Test RTQA software tools using this DICOM dataset
and the clinical validation test protocol.
30
RTQA platforms used by RTOG, EORTC or TROG:
VodcaRT from Medical Software Solutions
CERR software
ITC remote review tool
VelocityAI from Velocity Medical Solutions
Mim software from Mimvista
Artiview from Aquilab
Swan
RTQA software to be tested
31
Delegates from the manufacturers and
from the RTOG, EORTC and TROG
Proposed project members:
32
Draft project proposal: March 2009 till August 2009
Pilot validation tests of Vodca (EORTC): till July 2009
Full project proposal incl. finances: October 2009
Provisional timeline:
33
ITC remote review tool
CERR
Mim
vista
VelocityAI
RT
-View
Sw
an
VodcaRT
A joint effort!
34
A joint effort
35
11-13 March 2010
Barcelona, Spain
36
Thanks for your attention
ROG Executive CommitteeROG Executive Committee ROG + HQ / QART subcommitteeROG + HQ / QART subcommittee
Brigitta BaumertRadiation Oncologist
Maastro Clinic, MaastrichtThe Netherlands
Vincent Grégoire(Brussels)
Chair
Karin Haustermans(Leuven)
Post-chair
Edwin Aird Physics Co-chair
QA RT Team
Coen Hurkmans Physics Co-chair
QA RT SC
Philippe Maingon(Dijon)
Treasurer
Damien Weber Clinical Co-chair QA RT SC/Team
Please visit our websitesPlease visit our websiteshttp://www.eortc.be http://group.eortc.be/radio
Paul Fenton
37
The end
top related